Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes information about the Company’s stock options outstanding at June 30, 2018, and activity during the six months then ended:

						Weighted-
						Average
				Weighted-		Remaining		Aggregate
	Stock			Average		Contractual		Intrinsic
	Awards			Exercise Price		Life (Years)		Value
Balance as of December 31, 2017		3,156		$	4.96
Options granted		221		$	1.83
Options exercised		-		$	-
Options forfeited		(365	)	$	4.93
Options cancelled		(96	)	$	8.65
Balance as of June 30, 2018		2,916		$	4.60		7.06	$	430
Vested and expected to vest at June 30, 2018		2,916		$	4.60		7.06	$	430
Exercisable as of June 30, 2018		1,897		$	5.78		5.98	$	84

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The per-share fair value of each stock option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions:

	Three months ended June 30,						Six months ended June 30,
	2018			2017			2018			2017

Dividend yield		—			—			—			—
Risk-free interest rate		2.85	%		1.88	%		2.70% - 2.97	%		1.88% - 2.29%
Expected term (in years)		6-10			6			6 - 10			6 - 9
Volatility		89	%		77	%		89	%		77	%

Schedule of Unvested Restricted Stock Units Roll Forward

RSU activity for the period ended June 30, 2018 is summarized below:

	Number of Shares			Weighted- Average Grant Date Fair Value
Unvested as of January 1, 2018		617		$	1.65
Granted		79		$	1.78
Vested		(548	)	$	1.40
Forfeited		(70	)	$	2.85
Unvested at June 30, 2018		78		$	2.40

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Total stock-based compensation expense related to options and RSUs granted to employees and non-employees is included in the condensed consolidated statements of operations and comprehensive loss as follows:

	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
Sales and marketing	$	166	$	158	$	275	$	178
Research and development		47		82		225		184
General and administrative		189		283		794		557
Restructuring charges		-		186		-		186
	$	402	$	709	$	1,294	$	1,105